Pradox1000 mg/ml

Pradox is a cholinesterase reactivator (oxime) antidote used in the emergency management of poisoning by organophosphate compounds.

Established/FDA-approved use

• Antidotal treatment of poisoning by organophosphate pesticides and chemicals with anticholinesterase (acetylcholinesterase-inhibiting) activity, used as an adjunct to atropine and supportive care.
• Control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis (e.g., neostigmine, pyridostigmine), used as adjunct therapy.

Guideline-supported / combination-therapy use

• Management of nerve-agent (military-type organophosphate) exposure, given together with atropine as part of combined antidote kits, per public-health and military medical guidance.

Pradox must always be used together with atropine and appropriate decontamination and supportive care; it is not effective as a sole treatment for organophosphate poisoning.

Note: Pradox is not effective and is not generally recommended for poisoning caused by carbamate insecticides alone, since carbamate inhibition of cholinesterase is self-reversing.

Each vial of Pralidoxime Chloride for injection contains sterile, lyophilized Pralidoxime Chloride powder (commonly available in strengths such as 500 mg or 1 g per vial), intended for reconstitution with an appropriate diluent before administration. No preservative is typically present; exact formulation may vary by manufacturer.

Pradox (2-PAM chloride) is a quaternary ammonium oxime compound belonging to the cholinesterase-reactivator class of antidotes. It is used in emergency toxicology to reverse the effects of organophosphate compounds, found in certain pesticides, industrial chemicals, and nerve agents, that inhibit the enzyme acetylcholinesterase.

Pradox is supplied as a sterile powder for reconstitution and is administered by injection in a hospital or emergency-care setting under the supervision of trained medical personnel, always in combination with atropine and supportive measures.

Pradox belongs to the therapeutic class of antidotes, specifically the oxime cholinesterase reactivators, used in the treatment of organophosphate and certain anticholinesterase-drug toxicity.

Pralidoxime Chloride acts by reactivating acetylcholinesterase that has been inactivated (phosphorylated) by organophosphate compounds. It binds to the organophosphate-cholinesterase complex and displaces the phosphate group from the active site of the enzyme, restoring normal enzymatic and neuromuscular function.

The efficacy of Pralidoxime Chloride is highly time-dependent: once the phosphorylated enzyme undergoes a process called "aging" (an irreversible chemical change), reactivation is no longer possible. For this reason, Pralidoxime Chloride is most effective when administered as early as possible after exposure, typically within 24-36 hours, though earlier administration is preferred as aging can occur much sooner with certain agents.

Pralidoxime Chloride predominantly reverses nicotinic effects (muscle weakness, fasciculations, respiratory muscle paralysis) of organophosphate poisoning; it does not reverse muscarinic effects (excessive secretions, bradycardia, bronchospasm), which is why it must be co-administered with atropine.

Pradox is reconstituted and given by slow intravenous infusion (preferred), diluted in normal saline over 15-30 minutes; in emergencies with pulmonary edema, it may be given by slow IV injection over at least 5 minutes to avoid rapid-injection reactions. If intravenous access is not immediately available, intramuscular or subcutaneous injection may be used. Pradox should never be administered rapidly by IV push.

Pradox has a limited number of clinically significant interactions:

• Succinylcholine: Avoid concurrent use where possible; organophosphate poisoning itself reduces plasma cholinesterase activity (which may persist for 7-14 days), and use of ester-type muscle relaxants such as succinylcholine during this period can cause markedly prolonged neuromuscular blockade and apnea.
• Barbiturates: Their potentiation by anticholinesterase agents is reduced to some extent by Pradox, but caution is still warranted.
• Morphine, theophylline/aminophylline, reserpine, and phenothiazines: These should generally be avoided in patients with organophosphate poisoning being treated with Pradox, as they may worsen toxicity or respiratory depression.

At recommended doses, side effects of Pradox are usually mild and transient and can be difficult to distinguish from symptoms of the underlying poisoning. Reported effects include:

• Blurred vision, diplopia, and impaired accommodation
• Dizziness, drowsiness, and headache
• Nausea and dry mouth
• Mild tachycardia and a transient rise in blood pressure
• Hyperventilation and mild muscular weakness

Rapid intravenous injection of Pradox can cause laryngospasm, muscle rigidity, and tachycardia, which is why slow infusion or injection is required.

Formal reproduction studies with Pradox in pregnancy are limited. Because Pradox is used to treat life-threatening organophosphate poisoning, it should be used in pregnancy only if clearly needed, when the potential benefit to the mother justifies the potential risk to the fetus; a physician should be consulted whenever possible, though treatment should not be withheld in an emergency.

It is not known whether Pradox passes into breast milk. Use during breastfeeding should be guided by a physician, weighing the life-saving benefit of treatment against any potential risk to the infant.

• Pradox must be administered by, or under the direct supervision of, trained medical personnel in a hospital or emergency-care setting.
• It must always be used together with atropine and appropriate supportive care (airway management, oxygen, decontamination); Pradox is not a substitute for these measures.
• Administer as early as possible after exposure; delayed administration reduces effectiveness because the phosphorylated enzyme undergoes irreversible "aging."
• Pradox must be given slowly (by infusion or slow injection); rapid IV injection can cause tachycardia, laryngospasm, and muscular rigidity.
• Use with caution and reduced dosing in patients with renal impairment, since Pradox is cleared renally.
• Use with caution in patients with myasthenia gravis; an overdose of Pradox may precipitate a myasthenic crisis.
• Pradox is generally not effective for isolated carbamate insecticide poisoning and is not recommended in that setting unless organophosphate co-exposure is suspected.

Overdosage of Pradox may cause neuromuscular blockade, dizziness, blurred vision, diplopia, drowsiness, and elevated blood pressure. Since Pradox is used only in supervised emergency or hospital settings, suspected overdose should be managed immediately by the treating medical team with supportive care and continuous monitoring; if overdose is suspected outside a hospital setting, seek immediate emergency medical attention or contact a poison control center.

Store Pradox powder for injection at room temperature (below 30°C), protected from light and moisture, and keep out of reach of children. Once reconstituted, use the solution promptly as directed by the treating physician or pharmacist; do not use if the solution is discolored or contains particulate matter.

Renal impairment: Dose reduction and close monitoring are recommended, as Pradox is eliminated by the kidneys (see Precautions and Warnings).

Hepatic impairment: No specific dose adjustment is well established; use with clinical caution.

Elderly: No specific dose adjustment is established beyond general clinical judgment and monitoring of renal function.

Pregnancy and lactation: See Pregnancy and Lactation section.

Pediatric patients: See Pediatric Use section for weight-based dosing.

Treatment with Pradox is continued for as long as clinically indicated, guided by resolution of nicotinic signs (muscle weakness, fasciculations) and the patient's ongoing atropine requirement. Repeat doses may be given every 3-8 hours in the initial period, and continuous infusion or repeated dosing may be required for 24-48 hours or longer in severe poisoning, particularly with highly lipophilic organophosphates, under continuous hospital monitoring.

Pradox powder for injection is reconstituted with sterile water for injection (commonly 20 mL per 1 g vial, per manufacturer instructions) to form a solution of approximately 50 mg/mL. The reconstituted solution is then further diluted in normal saline (e.g., 100 mL) for intravenous infusion, or may be given undiluted by slow IV injection in emergencies (e.g., pulmonary edema). Use reconstituted Pradox solution promptly and inspect visually for particulate matter or discoloration before use.

Antidotes; Oximes; Cholinesterase reactivators.

Pralidoxime Chloride reactivates acetylcholinesterase enzyme that has been inhibited by organophosphate compounds, by binding to the phosphorylated enzyme and cleaving the phosphate-enzyme bond, thereby restoring normal breakdown of acetylcholine at nicotinic synapses. It is most effective before the phosphorylated enzyme complex "ages" into a form resistant to reactivation.

C

Pradox is used in children for the emergency treatment of organophosphate poisoning, in combination with atropine. The recommended pediatric dose is 20-50 mg/kg (up to a maximum single dose of 2 g), administered intravenously, diluted and infused, or by slow injection if pulmonary edema is present. Because organophosphate poisoning is life-threatening, Pradox is used in children of all ages when indicated, though formal controlled pediatric trials establishing safety and efficacy have not been conducted; use should be guided by a pediatric or toxicology specialist whenever possible.